Regulus Therapeutics, a clinical stage biopharmaceutical company headquartered in San Diego, California, is spearheading the discovery and development of drugs that target microRNAs to treat a range of diseases within the United States. Currently, the company has two product candidates in the works: RG-012, an anti-miR targeting miR-21, which is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease, and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. Moreover, Regulus Therapeutics is developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company was incorporated in 2007 and has been at the forefront of drug development with its innovative approach.
Regulus Therapeutics Inc's ticker is RGLS
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 51-200 employees working at Regulus Therapeutics Inc
It is regulusrx.com
Regulus Therapeutics Inc is in the Healthcare sector
Regulus Therapeutics Inc is in the Biotechnology industry
The following five companies are Regulus Therapeutics Inc's industry peers: